Shares of Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) traded up 7.8% during mid-day trading on Wednesday . The company traded as high as $0.20 and last traded at $0.19. 19,100 shares traded hands during trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Stock Up 7.8 %
The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86. The company’s 50 day moving average is $0.19 and its 200 day moving average is $0.19.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Further Reading
- Five stocks we like better than Vyant Bio
- What is a SEC Filing?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Why Invest in High-Yield Dividend Stocks?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
